All In Biotech

NDA 050444 · Rempex

Minocin

Minocycline Hydrochloride · Injection

Orphan

Last checked: Nov 20, 2026Latest source record: Mar 31, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1972

Oct 26, 1972

Approved uses

2

Original approval plus efficacy supplements

Registered trials

291

55 Phase 3, 18 recruiting

FAERS reports

5,244

4,626 serious, 1,747 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 11, 2025.

INDICATIONS AND USAGE MINOCIN ® Intravenous is indicated in the treatment of the following infections due to susceptible isolates of the designated bacteria: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following Gram-negative bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes . Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species . MINOCIN ® Intravenous is indicated for the treatment of infections caused by the following Gram-positive bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 21, 1975 Supplement 16 · Efficacy
  • Oct 26, 1972 Original approval
1 products under this application
  • MINOCIN · MINOCYCLINE HYDROCHLORIDE EQ 100MG BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Minocycline" as an intervention, any sponsor and status, largest first.

All 291 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,318
  • off label use1,216
  • drug intolerance988
  • pain948
  • rheumatoid arthritis946
  • nausea829
  • rash819
  • arthralgia812
  • drug hypersensitivity798
  • joint swelling762
  • fatigue758
  • condition aggravated711

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200491
200579
200656
2007111
200892
200973
201066
2011106
2012146
201379
201477
2015117
2016179
2017214
2018256
2019284
2020320
2021238
2022392
2023417
2024723
2025794
2026334

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Minocin* (Minocycline HCl)

2024 spending

$767K

Beneficiaries

55

206 claims

Per beneficiary

$13,950

$30.54 per unit

View as table
YearSpending
2020$169,237
2021$312,152
2022$363,862
2023$431,613
2024$767,255

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 692 on PubMed

Sponsor: Rempex

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.